« Return to News | Ethics/Regulatory

AAHRPP Revises Standards

Tuesday, October 6, 2009 08:16 AM

The Association for the Accreditation of Human Research Protection Programs (AAHRPP) issued the final version of the first major revision of its standards in its eight-year history.

 AAHRPP streamlined the number of standards and increased flexibility in how to interpret them. It added or strengthened standards on global research, conflict of interest, community-based research, and data and safety monitoring.

As part of AAHRPP’s own quality improvement initiative, it undertook a comprehensive review of the standards, something that is planned to occur regularly. While none of the new standards or revisions reflect major changes in the requirements for accreditation, the revisions do reflect a major regrouping of the standards, providing a more logical framework for a human research protection program (HRPP) and better definition of the primary roles and responsibilities of the entities that comprise an HRPP, according to Marjorie Speers, Ph.D., president and CEO of AAHRPP.

Overall, AAHRPP has reduced the number of standards from 22 to 15, and the number of elements from 77 to 60. The Final Revised Accreditation Standards are at aahrpp.org.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.